The Institute of Hematology & Blood Diseases Hospital in China is conducting a clinical trial to look at the safety and efficacy of Obinutuzumab (an anti-CD20 monoclonal antibody) in the treatment of adult patients over 18 years of age who have a diagnosis of primary immune thrombocytopenia (ITP) who have not responded adequately or relapsed after first-line treatment. Eligible participants should have received their diagnosis of ITP more than 3 months ago and must have a platelet count less than 30,000 measured within two days prior to administration of the trial drug.

https://www.clinicaltrials.gov/study/NCT05995054?cond=immune%20thrombocytopenia&aggFilters=status:rec&limit=100&page=1&rank=26

China

Actively Recruiting